

DOI:

**Full Paper****The influence of physicochemical properties of biomimetic hydroxyapatite on the in vitro behavior of endothelial progenitor cells and their interaction with mesenchymal stem cells****Joanna Maria Sadowska, Jordi Guillem-Marti, Maria-Pau Ginebra\***

Dr. Joanna Maria Sadowska, Dr. Jordi Guillem-Marti, Prof. Maria-Pau Ginebra  
Biomaterials, Biomechanics and Tissue Engineering Group  
Department of Materials Science and Metallurgical Engineering  
Universitat Politècnica de Catalunya (UPC)  
EEBE  
Av. Eduard Maristany 10-14, 08019 Barcelona, Spain.  
E-mail: maria.pau.ginebra@upc.edu

Dr. Joanna Maria Sadowska, Dr. Jordi Guillem-Marti, Prof. Maria-Pau Ginebra  
Barcelona Research Centre in Multiscale Science and Engineering  
Universitat Politècnica de Catalunya (UPC)  
EEBE  
Av. Eduard Maristany 10-14, 08019 Barcelona, Spain

Prof. Maria-Pau Ginebra  
Institute for Bioengineering of Catalonia (IBEC)  
The Barcelona Institute of Science and Technology  
Baldiri Reixac 10-12, 08028 Barcelona Spain.

Keywords: calcium phosphates, osteogenesis, angiogenesis, coculture

Calcium phosphate (CaP) substrates are successfully used as a bone grafts due to their osteogenic properties. However, the influence of the physicochemical features of CaPs in angiogenesis is frequently neglected despite it is a crucial process for bone regeneration. The present work focuses on analyzing the effect of textural parameters of biomimetic calcium deficient hydroxyapatite (CDHA) and sintered beta-tricalcium phosphate ( $\beta$ -TCP) such as specific surface area (SSA), surface roughness and microstructure on the behavior of rat endothelial progenitor cells (rEPCs) and their crosstalk with rat mesenchymal stem cells (rMSCs). The higher reactivity of CDHA resulted in low proliferation rates in mono- and cocultured systems. This effect was especially pronounced for rMSCs alone, and for CDHA

1 with fine microstructure. In terms of angiogenic and osteogenic gene expression, the  
2 upregulation of particular genes was especially enhanced for needle-like CDHA compared to  
3  
4 plate-like CDHA and  $\beta$ -TCP suggesting the importance not only of chemistry of substrate but  
5  
6 also its textural features. Moreover, the coculture of rEPCs and rMSCs on needle-like CDHA  
7  
8 resulted in early upregulation of osteogenic modulator *i.e.* protein deglycase 1 (DJ 1) what  
9  
10 might be a possible cause of overexpression of osteogenic- related genes on the same  
11  
12 substrate.  
13  
14  
15  
16  
17  
18

## 19 1. Introduction

20  
21  
22  
23 Bone healing is a complex process that involves multiple interdependent and overlapping-in-  
24  
25 time steps.<sup>[1]</sup> For instance, the timely angiogenesis serves not only as a source of oxygen and  
26  
27 nutrients, but also controls the recruitment and differentiation of stem cells, the osteoblastic  
28  
29 activity and consequently further new bone formation.<sup>[2,3]</sup> Therefore, the interplay between  
30  
31 vessel-forming endothelial cells (ECs) and bone-forming cells is critical during the bone  
32  
33 healing process. The ability of these cells to communicate, both through autocrine/paracrine  
34  
35 routes and through direct gap junctional cell-to-cell contacts, results in a tight coupling  
36  
37 between angiogenesis and osteogenesis.<sup>[2]</sup> For instance, mesenchymal stem cells (MSCs) and  
38  
39 osteoblasts secrete angiogenic factors such as vascular endothelial growth factor (VEGF),<sup>[4]</sup>  
40  
41 fibroblasts growth factor (FGF)<sup>[5]</sup> and protein deglycase 1 (DJ 1)<sup>[6]</sup> whose goal is to enhance  
42  
43 ECs proliferation and subsequent vessel growth. On the other hand, ECs express bone  
44  
45 morphogenetic protein 2 (BMP-2) and endothelin 1 (EDH 1), which fulfil dual function by  
46  
47 regulating angiogenesis as well as stimulating bone formation.<sup>[7-10]</sup>  
48  
49  
50 Despite the remarkable self-regenerative capacity of bone tissue, large defects cannot be  
51  
52 bridged unless some support structures, namely bone grafts, are implanted to support the  
53  
54 healing process. Calcium phosphates (CaPs) have been shown to be excellent synthetic bone  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

grafts, due to their close compositional resemblance to the mineral phase of bone.

Furthermore, some of them such as sintered  $\beta$ -TCP or low temperature CDHA<sup>[11,12]</sup> were reported to possess osteoconductive/osteoinductive properties that might foster the osteogenesis-related processes.

Great efforts have been made in CaPs research towards investigating to which extent and how their particular physicochemical features such as macroporosity, chemistry, ionic release/uptake, and surface topography affect the osteoinductive/osteoconductive potential.<sup>[13,14]</sup> Nonetheless, since bone healing process is complex, involving not only bone-forming cells but also immune or endothelial cells, the implant should actively participate in the former stages of bone regeneration exhibiting anti-inflammatory and angiogenic properties as well as stimulating the proper crosstalk between the different cell types implicated in restoring of bone function.

Recently, some advances have been made in modulating the angiogenic performance of CaP-based materials. The macroporosity,<sup>[15,16]</sup> functionalisation/loading of scaffold with biomolecules like RGD<sup>[16]</sup> or VEGF<sup>[17,18]</sup> or incorporation of ions like copper<sup>[19]</sup> or cobalt<sup>[20]</sup> have been investigated as strategies for potentiating the angiogenic features of CaPs.

Moreover, the *in vitro* prevascularisation of bone grafts was also studied as an interesting approach for the preparation of constructs with enhanced angiogenic performance. For instance, Chen *et al.* and Thein-Han *et al.* showed that coculturing of endothelial and bone forming cells on microporous calcium phosphate scaffolds had positive impact on stimulating the formation of microcapillary network as well as the expression of genes involved in both angiogenesis and osteogenesis.<sup>[16,21]</sup> Although the pathways involved in activation of positive crosstalk of endothelial and bone cells have been widely investigated,<sup>[22,23]</sup> little attention has been paid to the effect of particular features of CaPs on the angiogenic and osteogenic events in coculture conditions.

1 Therefore, the current study tackles two main goals. The first was to investigate to which  
2 extent the particular cues of CDHA affect the behaviour of endothelial progenitor and  
3  
4 mesenchymal stem cells separately. Two chemically identical biomimetic calcium deficient  
5  
6 hydroxyapatite, consisting of either needle-like or plate-like crystals were compared to  
7  
8 sintered  $\beta$ -TCP in terms of its effect on rEPCs and rMSCs proliferation, PECAM-1  
9  
10 production and osteogenic/angiogenic gene expression. As a second goal, the outcome of  
11  
12 physicochemical features of CaPs on the interaction of rEPCs and rMSCs were investigated  
13  
14 through coculture system evaluating angiogenic and osteogenic gene expression and the  
15  
16 secretion of connexin43, a junctional protein responsible for cell-to-cell communication.  
17  
18 Additionally, the expression of protein deglycase 1 (DJ 1) and endothelin 1 (EDH 1) was  
19  
20 analysed, as possible mediators of rEPCs and rMSCs crosstalk.  
21  
22  
23  
24  
25  
26

## 27 **2. Results**

### 31 **2.1. Physicochemical characterization of CaPs**

32  
33  
34  
35 The XRD diffraction confirmed that CaPs are phase-pure (**Figure 1C**) except for C-CDHA,  
36  
37 where traces of unreacted  $\alpha$ -TCP were observed (< 3%). The sintered  $\beta$ -TCP showed sharp  
38  
39 diffraction peaks whilst broad peaks were observed for C-CDHA and especially for F-CDHA  
40  
41 substrates. Whereas all materials presented similar porosities (Figure 1D), clear differences  
42  
43 were observed in terms of microstructure. C-CDHA consisted of plate-like crystals, whereas  
44  
45 F-CDHA presented nanometric sized needle-like crystals, organised in agglomerates. The  
46  
47 sintering process of  $\beta$ -TCP led to the formation of polyhedral crystals (Figure 1A). The  
48  
49 microstructural differences resulted in higher SSA for the biomimetic CDHA compared to  
50  
51 sintered  $\beta$ -TCP. C-CDHA presented higher average roughness values than F-CDHA and  
52  
53 sintered  $\beta$ -TCP ( $1.33\pm 0.23$ ) (Figure 1B).  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 2.2. Initial adhesion and proliferation in monocultures and cocultures

1  
2  
3  
4 Similar adhesion of monocultured rEPCs was observed in all substrates (**Figure 2A**).

5  
6 Monocultured rEPCs progressively increased their number in all CaPs with slightly slower  
7  
8 proliferation rate on biomimetic CDHA substrates. Moreover, lower number of monocultured  
9  
10 rEPCs on  $\beta$ -TCP at day 3 was observed compared to TCPS.

11  
12 In monocultured rMSCs, the cellular adhesion was lower on CDHA substrates whilst  $\beta$ -TCP  
13  
14 presented similar number of adhered cells compared to the control. Overall, the proliferative  
15  
16 potential of monocultured rMSCs was lower when cultured on CaP substrates. This scenario  
17  
18 was especially pronounced for biomimetic substrates where the cellular proliferation was  
19  
20 significantly slowed down or impaired on C-CDHA and F-CDHA, respectively. Moreover,  
21  
22 the  $\beta$ -TCP showed significantly lower number of monocultured rMSCs at day 21 compared to  
23  
24 the control.

25  
26 In coculture system, the cellular adhesion was also lower on CDHA compared to  $\beta$ -TCP and  
27  
28 TCPS. The cells presented low proliferation rate on biomimetic CDHA being this scenario  
29  
30 especially pronounced on F-CDHA, where similar cell numbers were observed over the cell  
31  
32 culture times. Nonetheless, the proliferative potential of cells on C-CDHA was higher on  
33  
34 coculture condition compared to monocultured rMSCs. The enhanced proliferation rate on  
35  
36 coculture was also observed for  $\beta$ -TCP compared to monocultured rMSCs.

## 2.3. Ionic concentration

37  
38 The evolution of calcium and phosphate concentration in the EGM-2 MV culture medium in  
39  
40 presence of cells is displayed in Figure 2B and 3C, respectively. The initial value of  $\text{Ca}^{2+}$   
41  
42 concentration was  $1.89 \pm 0.05$  mM. In general, irrespective of the cell type, little alteration of  
43  
44 calcium levels was observed for C-CDHA and  $\beta$ -TCP. In monocultured rEPCs, F-CDHA  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

uptook  $\text{Ca}^{2+}$  ions from the medium, this resulting in a 20% decrease in calcium concentration compared to the control throughout the whole culture period. In rMSCs monoculture, the decrease of  $\text{Ca}^{2+}$  by F-CDHA was observed at 6 h and 14 d of cell culture whilst this trend for coculture was noted at 6 h, 14 and 21 d.

The initial experimental value of  $\text{P}_i$  was  $1.02 \pm 0.01$  mM. In general, higher  $\text{P}_i$  levels were detected in presence of the biomimetic substrates, whereas the values registered for the  $\beta$ -TCP substrates were similar to TCPS. Despite using the same cell culture medium, different trends were observed for the biomimetic substrates depending on cell type. For rEPCs monoculture, the CDHA increased approximately 50% the  $\text{P}_i$  concentration compared to TCPS at 6 hours. In contrast, for rMSCs monoculture and coculture on biomimetic CDHA highest levels of  $\text{P}_i$  were observed at day 3, reaching approximately 170% and 130%  $\text{P}_i$  concentration compared to TCPS, respectively. Comparing the two biomimetic substrates, F-CDHA led to more pronounced changes of  $\text{P}_i$  content. In all cell culture conditions on CDHA, slow and progressive decrease of  $\text{P}_i$  concentration was observed after reaching the aforementioned highest levels.

## 2.4. Cell morphology

Cellular morphology in mono- and coculture on CaP substrates at 14 and 21 days were studied through visualisation with a CLSM. For that purpose, cells were stained for F-actin and nuclei (**Figure 3**). In all conditions, the cells presented a spread morphology with well-defined cytoskeleton except for monocultured rMSCs on F-CDHA at day 21.

Cx43, a gap-junction protein, was visualised in all CaP substrates over all cell culture conditions at days 14 and 21 (**Figure 4**). The analysis revealed that Cx43 protein was mainly colocalised with F-actin in cells cultured on CaPs being this scenario similar to that observed

1 in control group. In all conditions the presence of Cx43 was mainly localized in the outer part  
2 of the cellular membrane.  
3

4 In order to distinguish rEPCs at coculture conditions, cells were additionally incubated with  
5 endothelial specific PECAM-1 and compared to monocultured rEPCs (**Figure 5A**). Whilst  
6 PECAM-1 was well visible in rEPCs monoculture, a small number of PECAM-1 positively  
7 stained cells were observed in coculture. Semiquantitative analysis of CLSM images revealed  
8 that at day 14 the PECAM-1 stained area in rEPCs monoculture was slightly lower on C-  
9 CDHA and  $\beta$ -TCP sample whilst the F-CDHA showed similar values to that observed on  
10 control group (Figure 5B). In case of coculture, increased values of PECAM-1 stained area  
11 were observed for C-CDHA at day 14 (Figure 5C) compared to other CaPs and control. These  
12 differences between substrates were not statistically significant and they disappeared at day  
13 21.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

## 31 **2.6. Gene expression**

### 32 *2.6.1. Osteogenic gene expression*

33  
34  
35  
36  
37  
38 The expression of genes related to osteogenesis is depicted in **Figure 6**. In general, an  
39 upregulation of the osteogenic genes was detected on the CaP substrates, both in mono- and  
40 coculture conditions. A considerable upregulation of the ALP expression was observed on the  
41 F-CDHA substrate, irrespective of cell type. In monocultured rMSCs the maximum value was  
42 attained at day 1, decreasing at 7 and 14 days. In contrast, in monocultured rEPCs and in the  
43 cocultures the ALP expression increased at 1 and 7 days, strongly decreasing at day 14. The  
44 expression of BMP-2 was higher for monocultured rEPCs compared to the other culture  
45 conditions in all substrates at day 1, decreasing afterwards. Conversely, monocultured rMSCs  
46 and coculture continuously increased their BMP-2 expression until day 7, especially for F-  
47 CDHA, and they maintained similar levels at day 14 irrespective of the substrate. Regarding  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 OC expression, it was upregulated at early time points in the rEPCs, whilst in rMSCs and  
2 coculture the increase was shifted to 7 or 14 days. Moreover, the upregulation was higher on  
3 F-CDHA substrate in comparison to the other CaPs, irrespective of the cell type. The  
4 expression levels of DJ 1 were higher in the two CDHA substrates compared to  $\beta$ -TCP. These  
5 levels were especially high in monocultured rEPCs and coculture at day 1 in both C-CDHA  
6 and F-CDHA. Subsequently, they decreased in all substrates except for rEPCs cultured on F-  
7 CDHA. Monocultured rMSCs on C-CDHA showed also a high upregulation at day 7.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 *2.6.2. Angiogenic gene expression*

20  
21  
22

23 The expression of angiogenic markers is depicted in **Figure 7**. VEGF A was overexpressed by  
24 cells cultured on F-CDHA at all time points, especially by rEPCs but also in the 1:2  
25 rEPCs:rMSCs cocultures and in the rMSC monocultures. In contrast, the cells cultured on C-  
26 CDHA and sintered  $\beta$ -TCP produced similar VEGF A expression pattern: an initial peak at  
27 day 1, followed by a brusque decrease at days 7 and 14. The expression profile of VEGF R2  
28 was strongly dependent of cell type and substrate, although an overexpression was observed  
29 on all CaP substrates. In general, biomimetic substrates showed to cause more fluctuations in  
30 VEGF R2 expression rather than sintered  $\beta$ -TCP, which maintained similar VEGF R2 values  
31 over cell culture. For biomimetic CaPs, the overexpression of VEGF R2 was mainly observed  
32 in rEPCs monoculture presenting the highest values at days 7 and 14 for C-CDHA and F-  
33 CDHA, respectively. The expression of EDH 1 was strongly enhanced by F-CDHA at day 1  
34 and 7 for rEPCs monoculture and at day 14 for coculture. In contrast, overexpression of  
35 EDH1 was observed in the rEPCs monoculture on  $\beta$ -TCP at day 14.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

### 57 *2.6.3. The effect of rEPCs and rMSCs coculture on osteogenic and angiogenic gene* 58 *expression*

59  
60  
61  
62  
63  
64  
65



1 The effect of coculture on the expression of osteogenic and angiogenic markers is presented  
2  
3 in **Figure 8**. Upregulation of osteogenic markers in coculture condition was substrate and  
4  
5 gene dependent. In general, the F-CDHA substrate led to higher values of upregulation of  
6  
7 osteo-specific genes compared to other biomimetic C-CDHA and to sintered  $\beta$ -TCP. For F-  
8  
9 CDHA, the main upregulation peak of osteogenic genes was detected at day 1 or day 7 of  
10  
11 coculture. Both biomimetic C-CDHA and sintered  $\beta$ -TCP showed similar patterns for BMP-2,  
12  
13 OC and DJ 1 showing dual upregulation peak at day 1 and 14.  
14  
15

16  
17 With regards to angiogenic gene expression, the coculture of rEPCs and rMSCs resulted in  
18  
19 strong upregulation of VEGF R2 and EDH 1 when the cells were cultured on F-CDHA and  $\beta$ -  
20  
21 TCP, mainly at day 14 of coculture. The expression of EDH 1 was enhanced by F-CDHA  
22  
23 whilst VEGF R2 expression was upregulated by both F-CDHA and  $\beta$ -TCP substrates (Figure  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3. Discussion

#### 3.1. Proliferation of rEPCs and rMSCs on the different substrates

66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

EGM-2.<sup>[30–32]</sup> Moreover, the use of the same culture medium for all cultures is a clear advantage when comparing bioactive materials, which are known to interact with the cell culture medium. Using a single cell culture medium allows discarding any interactions due to the interaction of the material with the cell culture media of different compositions.

The analysis of cell behaviour on CaP substrates requires to take into consideration not only their physicochemical features but also their intrinsic reactivity with aqueous environment. The reactive behaviour of CaPs *in vitro* and its further effect on bone cell behaviour, more pronounced for substrates with high SSA, has been widely reported.<sup>[13,33–35]</sup> For instance, we previously showed that CDHA altered ionic concentration to a higher extent than sintered ceramics<sup>[36]</sup>, which can be related not only to the high SSA, but also to the presence of non-apatitic domains on their crystal surface.<sup>[37,38]</sup> Moreover, the distinct structural features of chemically identical substrates used in the present study, *i.e.* F-CDHA and C-CDHA, might produce different ionic fluctuations and thereby affect the cellular behaviour to different extents. Another interesting issue is that expected ionic fluctuations might vary depending of medium composition<sup>[34,36]</sup> as well as presence or not of cells<sup>[39]</sup>. In the latter case, the layer of cells might reduce the exposure of the substrate to different extents depending on the degree of surface coverage, which in turn would decrease the ionic exchange.<sup>[40]</sup> In the current study we observed that CDHA substrates released  $P_i$ , and in agreement with a previous work,<sup>[41]</sup> this trend was more pronounced for F-CDHA than for C-CDHA, due to its higher SSA. This behaviour can be associated with the incorporation of B-type carbonate into the apatite lattice, replacing phosphate groups, as demonstrated in a previous study.<sup>[41]</sup> In fact, the release of  $P_i$  also occurred in absence of cells, as displayed in Figure S2.

Interestingly, although the monocultures and coculture on CaPs were performed using the same cell culture medium, the release of  $P_i$  was different in the different cultures. While the trends of  $P_i$  release observed for biomimetic substrates with monocultured rMSCs and coculture were similar to those without cells, the monocultured rEPCs decreased the  $P_i$

1 release 2-fold for both F-CDHA and C-CDHA. However, since little differences of cellular  
2 adhesion on the biomimetic CDHA were observed at 6 hours of cell culture, the different  $P_i$   
3  
4 release cannot be explained with the hypothesis that the layer of cells might cover the surface  
5  
6 of substrate reducing the ionic exchange.<sup>[40]</sup> Therefore, the different ionic behaviour observed  
7  
8 in monocultured rEPCs could be attributed to the cellular activity. For instance, the  
9  
10 endothelial cells exhibit the capacity to uptake  $P_i$  in hyperphosphatemia what increases the  
11  
12 apoptosis rate.<sup>[42,43]</sup>

13  
14  
15  
16 On another hand, given the calcium- deficient nature of CDHA substrates, an uptake of  
17  
18 calcium from the cell culture medium triggered by the maturation of hydroxyapatite was  
19  
20 expected, as proved in previous works using other cell culture media.<sup>[41]</sup> However, little  
21  
22 depletion of this ion was observed. This can be explained by the high  $Mg^{+2}$  content in the  
23  
24 EGM-2 MV culture medium, which resulted in the uptake of this ion by the substrate, which  
25  
26 likely mitigated the uptake of calcium, as shown in Figure S2.

27  
28  
29  
30  
31 In our study, monocultured rEPCs showed similar proliferative potential on all CaPs with  
32  
33 slightly lower proliferation rate for biomimetic substrates (Figure 2 and 3). Previous studies  
34  
35 with bioinert substrates showed that topographical cues of biomaterials have little impact on  
36  
37 proliferation of endothelial cells.<sup>[44]</sup> For instance, Xu *et al.* observed similar adhesion and  
38  
39 proliferation of ECs cultured on randomly electrospun PLLA substrates with either nano- or  
40  
41 micro-roughness.<sup>[44]</sup> It is important to highlight that, unlike in the case of inert materials,  
42  
43 calcium phosphates control cellular behaviour also through fluid-mediated effects *i.e.* the  
44  
45 ionic exchange with cell culture medium. For instance, the depletion of magnesium in case of  
46  
47 biomimetic CDHA (Figure S2) may result in the lower proliferative potential of monocultured  
48  
49 rEPCs, since this particular ion was reported to be vital in modulating endothelial cell  
50  
51 behaviour.<sup>[45,46]</sup> Other possible explanation for slowed proliferation of rEPCs on these  
52  
53 substrates might be an uptake of  $P_i$  by cells what in turn results in apoptosis.<sup>[42,43]</sup>

1 In contrast, reduced proliferation was observed for biomimetic substrates in comparison to  $\beta$ -  
2 TCP in rMSCs monoculture. This might be attributed to two simultaneously affecting factors:  
3  
4 the microstructure of CDHA and its intrinsic ionic reactivity. We previously demonstrated  
5  
6 that ionic fluctuations caused by CDHA particularly affect rMSCs causing a reduction on the  
7  
8 number of focal adhesions and cell shrinkage and leading to cell death via apoptosis.<sup>[36,41]</sup>  
9  
10 Interestingly, although the F-CDHA possesses the same chemical composition as C-CDHA, it  
11  
12 led to a more pronounced reduction of MSCs number. A similar behaviour was previously  
13  
14 observed for osteoblastic cells.<sup>[47]</sup> The more pronounced release of  $P_i$  caused by F-CDHA due  
15  
16 to its smaller crystal size and thus the higher SSA could be the responsible for this reduced  
17  
18 proliferation. For instance, Liu *et al.* demonstrated that even small changes of  $P_i$   
19  
20 concentrations in cell culture medium reduce the proliferation of MSCs.<sup>[48]</sup> The effect of  
21  
22 topography on cellular proliferation cannot be overlooked. For instance, we previously  
23  
24 demonstrated that the contact of cells with topography of CaP substrate slowed down the  
25  
26 proliferation rate compared to cells exposed exclusively to CaP extracts without the additional  
27  
28 effect of microstructure.<sup>[36]</sup>  
29  
30 Slowed cell proliferation on coculture system was also observed for CDHA, also especially  
31  
32 for F-CDHA. Since the greater part of cells was constituted of rMSCs, we hypothesize that  
33  
34 this behavior can be also attributed to microstructure and ionic fluctuations of CDHA as  
35  
36 above described for the rMSCs monoculture. Interestingly, the PECAM-1 staining revealed  
37  
38 few number of rEPCs in coculture system, irrespective of the substrate (Figure 5). The  
39  
40 possible explanation of this scenario might be the growth rate of cells that might change when  
41  
42 exposed to coculture conditions.<sup>[24]</sup> Bidarra *et al.* showed that MSCs and ECs cultured alone  
43  
44 exhibited different proliferation rate as when they were cocultured. The authors observed that  
45  
46 ECs stimulated the expansion of MSCs what might contribute to curtail ECs capability to  
47  
48 grow in coculture. This led to lower proliferation rate for EC in coculture compared to EC in  
49  
50 monolayer what was also observed in our study.<sup>[24]</sup> Similarly, Fuchs *et al.* demonstrated low  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 proliferative potential of ongrowth endothelial cells (OECs) when exposed to coculture  
2 conditions. Coculturing bone cells with OECs at ratio 3:2 lead to two opposite behaviors:  
3  
4 whilst bone cells increased their number over time, a decrease was observed for OECs.<sup>[47]</sup> In  
5  
6 our study, the low number of rECPs was interestingly observed in both CaPs and control  
7  
8 group (Figure 5). The high proliferation rate of coculture for control group and  $\beta$ -TCP  
9  
10 combined with low number of PECAM-1 positively stained cells suggest an increased growth  
11  
12 of MSCs what might contribute to curtail effect over rEPCs (Figure 2A). Instead, the low  
13  
14 cellular number of coculture observed on CDHA substrates suggests other parameters  
15  
16 involved in reducing the rEPCs proliferation since this cannot be associated with increased  
17  
18 rate of rMSCs proliferation. One possible explanation for this scenario might be the increased  
19  
20 levels of phosphate from CDHA, since levels above 2.5 mM were reported to induce  
21  
22 apoptosis in ECs.<sup>[43,50]</sup>  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **3.2. Angiogenic differentiation of rEPCs and rMSCs on the different substrates**

32  
33  
34  
35

36 In order to evaluate the angiogenic potential of CaPs, the expression of VEGF A and VEGF  
37  
38 R2 was measured in mono- and coculture conditions (Figure 7). Additionally, cell cultures  
39  
40 were subjected to the endothelial specific PECAM-1 staining to reveal whether rEPCs form  
41  
42 microcapillary-like structures on CaP substrates (Figure 5).  
43  
44

45 VEGF A plays a pivotal role in the angiogenesis process, regulating the recruitment of  
46  
47 endothelial progenitor cells as well as promoting its proliferation and differentiation.<sup>[23]</sup>  
48  
49

50 VEGF A has been also suggested to mediate the secretion of osteogenic factors such as BMP-  
51  
52 2, thus stimulating bone cell behaviour.<sup>[51]</sup> Interestingly, VEGF A is known to be expressed  
53  
54 not only by endothelial cells, but also by pre-osteoblasts during differentiation,<sup>[52]</sup> thereby  
55  
56 paracrinely stimulating angiogenesis. In our study, early VEGF A overexpression at 1 day  
57  
58 was found when rEPCs were cultured on biomimetic substrates, notably more pronounced on  
59  
60  
61  
62  
63  
64  
65

1 F-CDHA (Figure 7). Whilst rEPCs cultured on C-CDHA showed a decrease of VEGF A after  
2 1 day expression peak, rEPCs on F-CDHA sustained high values of VEGF A. Furthermore,  
3 VEGF A expression was also upregulated for monocultured rMSCs and coculture on F-  
4 CDHA. This behaviour was not observed for other CaP substrates. Several authors studied the  
5 effect of bioactive character of substrates such as bioglasses on high expression of VEGF A in  
6 endothelial cells. However, they rather point the stimulatory effect of the release of calcium,  
7 which was not altered in our study.<sup>[53,54]</sup> On the other hand, the surface roughness also plays  
8 an important role in regulating angiogenic gene expression. For instance, the upregulation of  
9 VEGF A was observed in bioinert materials with surface roughness (Ra) of approximately 2  
10  $\mu\text{m}$ .<sup>[55]</sup> Although the bioactive character of CDHA hinder to interrelate the enhanced VEGF A  
11 expression with the topography of the substrate, we hypothesize that the roughness of CDHA  
12 might contribute to present scenario. The expression of VEGFR2 as the main receptor and  
13 major mediator of the angiogenic effects of VEGF on endothelial cells<sup>[56,57]</sup> was also studied.  
14 We found that the enhanced expression of VEGF A from endothelial cells cultured on F-  
15 CDHA substrate correlated with higher levels of their VEGFR2 at early time of cell culture.  
16 Interestingly, strongly enhanced values of VEGF A at 1 day for monocultured rEPCs on F-  
17 CDHA (Figure 7) also corresponded in time with upregulation of EDH 1 and DJ 1 (Figure 6)  
18 as well as sustained expression of BMP-2 (Figure 6)- potent angiogenic inducers.<sup>[8,58]</sup> Hence,  
19 we hypothesize that greater expression of VEGF A might be coupled with combined effect of  
20 the enhanced expression of these genes as well as upregulation of VEGF R2. For instance,  
21 Kim *et al.* demonstrated a positive effect of DJ 1 on VEGF A expression in endothelial cells  
22 through involvement of autocrine and paracrine mechanisms.<sup>[6]</sup>  
23  
24 Positively PECAM-1 stained cells were observed in both monocultured rEPCs and cocultured  
25 conditions (Figure 5A). Nevertheless, we did not observe capillary-like networks in any of the  
26 studied CaP substrate. In both mono- and coculture conditions rEPCs were present in the form  
27 of patches rather than showing aligned morphology.

### 3.3. Osteogenic differentiation of rEPCs and rMSCs on the different substrates

The commitment of mono and cocultured rEPCs and rMSCs towards osteoblastic lineage was also evaluated through RT-qPCR. Alkaline phosphatase (ALP) expression and osteocalcin (OC) are commonly used markers of early and late osteogenic gene expression, respectively. Whilst ALP is implicated in the regulation of local concentrations of inorganic phosphates fostering the mineralization,<sup>[59]</sup> OC regulates the quality and size of newly-formed mineral crystals.<sup>[60]</sup> Since the number of rMSCs on the different substrates was relatively low during all the cell culture time points, we were not able to measure the ALP activity. The gene expression of BMP-2 and DJ 1 were also evaluated since both participate in osteogenesis process as well as they are potent enhancers of angiogenesis.<sup>[6,61,62]</sup>

Different trends of expression of ALP, OC, BMP-2 and DJ 1 were observed for mono and coculture conditions (Figure 6). Moreover, the expression of each individual osteogenic marker was also time- and substrate-dependent. In general, cells cultured on CaPs materials showed higher gene expression at early time point compared to TCPS. This effect was observed for both mono- and coculture condition being more pronounced for biomimetic substrates. The result is coincident with other studies where stimulatory effect of CaPs on osteogenic expression was demonstrated.<sup>[41,63]</sup> For instance, we previously reported that biomimetic materials induce the differentiation of MSCs to greater extent than sintered ceramic.<sup>[36]</sup> This stimulatory effect is likely due to the coupled effect of subtle ionic fluctuations and surface topography- pivotal parameters in controlling osteogenic cell commitment.<sup>[64,65]</sup> The little changes of calcium content in EGM-2 MV medium after immersion of CDHA allowed the cell survival and further differentiation. This agrees with our previous finding where differentiation of MSCs into osteoblastic lineage cultured on CDHA was observed only when great ionic changes were mitigated. Interestingly, although

1 both biomimetic CDHA own the same chemistry, the osteogenic differentiation was more  
2 pronounced for needle-like F-CDHA substrate suggesting the important role of surface  
3 topography.<sup>[47]</sup> This scenario, indeed, might contribute to curtail proliferation rate of MSCs  
4 (Figure 2A) inasmuch as osteogenic differentiation is usually accompanied by slower cellular  
5 proliferation.  
6  
7  
8  
9  
10

### 11 **3.4. Angiogenic and osteogenic differentiation of rEPCs and rMSCs in coculture**

12  
13  
14  
15  
16  
17  
18 The impact of coculturing rEPCs with rMSCs on angio- and osteogenesis was depicted in  
19 Figure 8. Overall, the F-CDHA stimulated to a greater extent the gene expression in coculture  
20 conditions compared to rMSCs monocultured on the same substrate. Interestingly, this  
21 upregulation was more pronounced for osteogenic-related genes, which were upregulated  
22 either at 1 day (BMP-2, OC and DJ1) or 7 days (ALP and OC) (Figure 8). Regarding the  
23 angiogenic gene expression, there were no impact of coculturing rEPCs and rMSCs on  
24 upregulation of VEGF A, the main regulator of angiogenic events, on any of studied CaP  
25 substrates.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 The previous reports showed that there are several parameters that might orchestrate this  
38 behavior in coculture. For instance, Villars *et al.* underlined that a direct cell contact, through  
39 gap junctional proteins like Cx43, is a fundamental condition for stimulation of gene  
40 expression in endothelial and bone cells in *in vitro* coculture systems.<sup>[66]</sup> However, since  
41 monocultured and cocultured cells presented similar secretion of Cx43 (Figure 4), the  
42 enhanced expression of osteogenic genes for coculture on F-CDHA should be attributed to  
43 other events that orchestrate this behavior. The great influence of potent osteogenic enhancers  
44 like BMP-2, EDH 1 and DJ 1 was also mentioned in literature. Kaigler *et al.* demonstrated  
45 that direct cell-cell contact mediate BMP-2 signaling from endothelial cells enhancing the  
46 ALP activity and OCN production of bone cells.<sup>[67]</sup> The effect of EDH 1, although frequently  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 associated only with angiogenic events, was also reported to stimulate differentiation of  
2 osteoprogenitor cells.<sup>[23]</sup> Moreover, previous reports demonstrated that DJ 1 not only mediates  
3  
4 the endothelial- bone cells' crosstalk but also induces osteogenesis through FGFR-1  
5  
6 signaling.<sup>[6]</sup> Since no enhanced expression of BMP-2 and EDH 1 in coculture was observed  
7  
8 for F-CDHA substrate we hypothesize that the higher levels of DJ 1 might contribute to the  
9  
10 osteogenic potential of F-CDHA.  
11  
12  
13

#### 14 15 16 17 **4. Conclusion**

18  
19 The results demonstrate that distinct chemical features of CaPs substrate trigger various cell  
20  
21 responses in terms of proliferation as well as angiogenic and osteogenic gene expression. In  
22  
23 general, ionically more reactive CDHA affect proliferation rate to greater extent than sintered  
24  
25  $\beta$ -TCP. The F-CDHA led to more pronounced ionic changes than C-CDHA significantly  
26  
27 reducing proliferation rate of rMSCs and the coculture of rECPs: rMSCs. For  $\beta$ -TCP, where  
28  
29 cells were exposed to little ionic exchange, the coculture resulted in enhanced growth of  
30  
31 rMSCs compared to monocultured rMSCs.  
32  
33

34  
35 With regards to coculture condition, the cellular crosstalk was not reflected in enhanced  
36  
37 secretion of gap junctional protein Cx43 but through upregulation of osteogenic-related genes.  
38  
39 This behavior was mainly observed for F-CDHA substrate and might be related to enhanced  
40  
41 expression of osteogenic inducer DJ 1.  
42  
43  
44  
45  
46

#### 47 48 **5. Experimental Section**

49  
50  
51 *Determination of coculture ratio of rEPCs and rMSCs:* For the coculture studies, both cell  
52  
53 types were expanded separately in their corresponding cell culture media till 70-80% of  
54  
55 confluence. Afterwards, rEPCs and rMSCs were detached and seeded at rEPCs:rMSCs ratios  
56  
57 of 1:0, 4:1, 2:1, 1:1, 1:2, 1:4 and 0:1 onto 24-well plates. Cells were cultured up to 21 days in  
58  
59  
60  
61  
62

EGM-2 MV medium at 37 °C in a humidified 5% CO<sub>2</sub> incubator replacing the medium every other day. The optimum ratio for coculture conditions was chosen evaluating cell proliferation, cell differentiation, and cell mineralization. The details regarding methods applied for quantification of cellular behaviour in coculture conditions were provided in Supplementary Information.

*Material preparation:* CDHA was obtained by hydrolysis of  $\alpha$ -tricalcium phosphate ( $\alpha$ -TCP) via a cementitious reaction, as previously described.<sup>[68]</sup> Briefly,  $\alpha$ -TCP powder was prepared by heating at 1400°C for 15 h a 2:1 molar mixture of calcium hydrogen phosphate (CaHPO<sub>4</sub>, Sigma-Aldrich, St. Louis, USA) and calcium carbonate (CaCO<sub>3</sub>, Sigma-Aldrich, St. Louis, USA), followed by quenching in air.  $\alpha$ -TCP powders with two different sizes were obtained by milling according to two different protocols. The  $\alpha$ -TCP powder with larger size (coarse, C: 5.2 $\mu$ m median size) was obtained by milling in agate ball mill (Pulverisette 6, Fritsch GmbH) with 10 balls (d=30 mm) for 15 min at 450 rpm. The  $\alpha$ -TCP powder with smaller size (fine, F: 2.8  $\mu$ m) was first milled with 10 balls (d=30 mm) for 60 min at 450 rpm followed by second milling with 10 balls (d=30 mm) for 40 min at 500 rpm and the third one with 100 balls (d=10 mm) for 60 min at 500 rpm.<sup>[69]</sup>

CDHA discs were obtained by mixing a solid phase consisting of  $\alpha$ -TCP powder and 2 wt.% of precipitated hydroxyapatite (PHA; Merck 2143, Merck, Darmstadt, Germany) with a liquid phase of 2.5 wt.% disodium hydrogen phosphate (Na<sub>2</sub>HPO<sub>4</sub>, Merck, Darmstadt, Germany), with a liquid to powder ratio of 0.35 mL g<sup>-1</sup>. The paste was transferred to Teflon moulds (15 mm diameter and 2 mm thickness) and immersed in water at 37 °C for 7 days for complete reaction. The products obtained were coded as C-CDHA or F-CDHA depending on the size of the starting powder.

$\beta$ -tricalcium phosphate discs were obtained by sintering C-CDHA at 1100°C for 15 hours, followed by slow cooling inside the furnace.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

*Material characterization:* Phase composition of the different CaPs was assessed by X-ray diffraction (XRD, D8 Advance, Bruker, Karlsruhe, Germany). The diffractometer equipped with a Cu K $\alpha$  X-ray anode was operated at 40 kV and 40 mA. The data was collected in 0.02° steps over the 2 $\theta$  range of 10°-80° with a counting time of 4s per step. The phases were identified by comparison to the diffraction patterns of HA (JCPDS 82-1943),  $\alpha$ -TCP (JCPDS 09-0348) and  $\beta$ -TCP (JCPDS 70-2065). Semiquantitative XRD analysis of the products was carried out using the reference intensity ratio method.<sup>[70]</sup> The microstructure of materials was analyzed by Scanning Electron Microscopy (SEM, Zeiss Neon 40, Oberkochen, Germany) at an acceleration voltage of 5 kV. To impart conductivity, surfaces were coated with gold-palladium layer prior to imaging. The surface roughness was characterized by optical interferometry (Veeco Wyko NT1100), using a 50x magnification and a scanned area of 47.5 x 63.4  $\mu\text{m}^2$ . Images were acquired using Vision32 software. The SSA and porosity of materials used in current study was described in previous reports.<sup>[71]</sup>

*Cell culture study:* The protocol of isolation of rat mesenchymal stem cells (rMSCs) and rat endothelial progenitor cells (rEPCs) was described elsewhere.<sup>[72]</sup> Briefly, cells were obtained from the tibias and femurs of Lewis rats at the Institute for Bioengineering of Catalonia (IBEC). Flow cytometry was performed in order to assess cell phenotype.<sup>[73]</sup> rMSCs were grown in Advanced Dulbecco's Modified Eagle Medium (AdvDMEM) supplemented with 10% of foetal bovine serum (FBS), 2 mM L-glutamine, penicillin/streptomycin (50 U mL<sup>-1</sup> and 50  $\mu\text{g mL}^{-1}$ , respectively) and 20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, provided from Invitrogen. rEPCs were expanded in microvascular endothelial cell medium 2 (EGM2-MV, Lonza) containing endothelial cell basal medium (EBM-2, Lonza) supplemented with EGM-2 bullet kit and 5% FBS.

All experiments, except where stated, were performed with a seeding density of  $12 \times 10^3$  cells per well using rMSCs and rEPCs at passages 3-5.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

*Monoculture and coculture of rEPCs and rMSCs on CaPs:* C-CDHA, F-CDHA and  $\beta$ -TCP discs (12-15 mm of diameter, 2 mm of height) were sterilised with 70% ethanol, rinsed with PBS and pre- incubated overnight with complete EGM-2 MV medium at 37 °C. Subsequently the corresponding cells were seeded on the substrates. The ratio 1:2 was used for coculture condition on discs considering the results obtained in the previous study. For both coculture<sup>[64]</sup> and monoculture of rEPCs and rMSCs,<sup>[31]</sup> EGM-2 MV medium was used. In all assays, the medium was refreshed after 6 hours of cell adhesion and then every other day throughout the whole culture period. Tissue culture polystyrene (TCPS) was used as corresponding control for each culture/co-culture condition. Cell number was evaluated at 6 hours, 3, 7, 14 and 21 days by measuring LDH activity following the previously detailed protocol (See Supporting Information). In order to express the absorbances' values as a cell number, individual calibration curves with a decreasing number of cells was prepared for each condition *i.e.* rEPCs monoculture, rMSCs monoculture and 1:2 rEPCs:rMSCs coculture. For cells cultured on CaPs discs, results were normalised versus the area of the discs and then expressed as relative fold to TCPS at 6h.

*Ionic concentration of cell culture media:* At specific time points, the supernatants from mono- and cocultures on CaPs were collected and stored at -20 °C for further analysis. Subsequently, the concentration of calcium and phosphorus were determined. The  $\text{Ca}^{2+}$  was quantified applying o- cresolphthalein complexone method.<sup>[74,75]</sup> The concentration of  $\text{P}_i$  was evaluated by Phosphate Colorimetric Assay Kit (Sigma- Aldrich) measuring the absorbance at 650 nm with Synergy HTX multi-mode microplate reader (Bio-Tek Instruments, Inc.). The changes in concentrations of calcium and phosphate for CaP substrates immersed in EGM-2 MV medium was also monitored without presence of cells up to 14 days. Since CDHA might also uptake other ions<sup>[41]</sup>, the content of magnesium was additionally determined through Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES, 5100 ICP-OES,

Agilent). Prior to quantification, the supernatants was diluted 20-fold with 2% of ultrapure nitric acid (Sigma-Aldrich).

*Immunostaining:* Monocultured rEPCs, rMSCs and coculture were stained for nuclei, F-actin and Connexin43 (Cx43). Monocultured rEPCs and coculture were additionally incubated with endothelial specific platelet endothelial cell adhesion molecule (PECAM-1, CD31). The staining was performed at 14 days and 21 days of cell culture. The samples were rinsed with PBS (x3) and cells were fixed with 4% (v/v) PFA solution in PBS. Afterwards, the permeablization process was carried out with 0.1 % Triton X- 100 (Sigma-Aldrich) in PBS during 15 min. Subsequently, cells were incubated 30 min at RT with blocking solution consisting of 1% bovine serum albumin (BSA) (Sigma-Aldrich) in PBS. The discs were incubated with the primary antibody rabbit anti- PECAM-1 (Santa Cruz Biotechnologies) at 1:100 in 1% BSA in PBS for one hour. The step was followed by incubation with secondary antibody Alexa Fluor 488 chicken anti- rabbit (1:1000) and Alexa Fluor 546 Phalloidin (1:300) in 0.1% Triton X- 100 in PBS (all from Invitrogen). For nuclei staining, 4',6-diamidino-2-phenylindole (DAPI) (1:1000 in 0.15% glycine in PBS) was added and samples were incubated for 2 minutes. Between all steps, three rinses for 5 minutes with 0.15% glycine (Sigma-Aldrich) in PBS were performed. For Cx43 staining the manufacturer instructions was followed in terms of cell fixation, dilution and incubation times. The primary antibody was mouse-anti Connexin43 C terminus (Millipore) and the secondary antibody was Alexa Fluor 488 goat anti- mouse (Invitrogen). The cells seeded on glass coverslip were used as a control group. Samples were mounted with Mowiol 4-88 (Sigma- Aldrich) and visualised using inverted LSM 800 ZEISS confocal microscope (CLSM). Images were acquired using LASX software and processed using Fiji/Image-J package.

*Angiogenic and osteogenic gene expression of cocultured rEPCs and rMSCs on CaPs:*

Angiogenic and osteogenic gene expression was evaluated at 1, 7 and 14 days of mono- and cocultures by quantitative real-time polymerase chain reaction (RT-qPCR). Total RNA was

1 extracted from mono and cocultures at the given time points using RNeasy<sup>®</sup> Mini Kit  
 2 (Qiagen, Hilden, Germany) as recommended by the manufacturer. Total RNA quantity was  
 3  
 4 determined by NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Montchanin,  
 5 DE, USA) and subsequently 130 ng of the total RNA were used as template for single strand  
 6  
 7 complementary DNA (cDNA) synthesis using QuantiTect Reverse Transcription Kit (Qiagen).  
 8  
 9 Quantitative real-time PCR (RT- qPCR) assays were performed and monitored in triplicate  
 10  
 11 using a StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).  
 12  
 13 The cDNA template was amplified with the QuantiTect SYBR Green RT-PCR Kit (Qiagen)  
 14  
 15 and specific primers for angiogenic and osteogenic markers (Listed in Table S1). No-RNA  
 16  
 17 control, the melt curve analysis and no-RT control were run to ensure the specificity of  
 18  
 19 primers and the absence of genomic DNA, respectively. The expression of all studied genes  
 20  
 21 were normalized by expression of  $\beta$ -actin (ACTB) and relative fold changes (FC) were  
 22  
 23 related to 1 day gene expression value of either rEPCs monocultured on TCPS with EGM-2  
 24  
 25 MV (for angiogenesis markers: VEGF A, VEGF R2, endothelin-1) or rMSCs monocultured  
 26  
 27 on TCPS with advDMEM (for osteogenic markers: ALP, BMP-2, OC, DJ 1). The fold change  
 28  
 29 was calculated with the formula  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40

$$41 \quad FC = E_{\text{target}}^{\Delta Cq_{\text{target}}(\text{TCPS } 6\text{h} - \text{sample})} / E_{\text{reference}}^{\Delta Cq_{\text{reference}}(\text{TCPS } 6\text{h} - \text{sample})}. \quad (1)$$

42  
 43  
 44  
 45  
 46 Cq represents the median value of the quantification cycle of the triplicate of each sample. E  
 47  
 48 corresponds to the efficiency of amplification and is determined through following formula  
 49  
 50  
 51  $E = 10^{[-1/\text{slope}]}$  where slope value proceeds from slope of the log-linear portion of the  
 52  
 53 calibration-curve.  
 54  
 55

56 *Statistical analysis:* Each experiment was performed in two independent runs except for the  
 57  
 58 immunostaining and ionic content without presence of cells for which one experiment was  
 59  
 60 performed for n=2 and n=3, respectively. Proliferation, ionic content in presence of cells and  
 61

1 gene expression data were plotted as means  $\pm$  SE with n=6. PECAM1 area was plotted as  
2 means  $\pm$  SE with n=10. Normality was checked through the Saphiro–Wilk test. Statistical  
3  
4 significance was determined by ANOVA with Tukey HSD post-hoc analysis. Non-parametric  
5  
6 data was additionally subjected to Kruskal Wallis test followed by multiple pairwise  
7  
8 comparison. Significance level for all tests was set for  $p < 0.05$ . Statistical analysis were  
9  
10 performed using SPSS 23.0 software (SPSS, ICN., Chicago, IL).  
11  
12  
13  
14  
15  
16

### 17 **Supporting Information**

18 Supporting Information is available from the Wiley Online Library or from the author.  
19  
20  
21  
22  
23

### 24 **Acknowledgements**

25  
26  
27 The authors acknowledge the Spanish Government for financial support through project, co-  
28 funded by the EU through European Regional Development Funds, and FPI scholarship of  
29  
30 JMS. They also thank the Generalitat the Catalunya for funding through project 2017SGR-  
31  
32 1165. MPG acknowledges the o by the Generalitat de Catalunya.  
33  
34  
35  
36  
37  
38  
39

40 Received: ((will be filled in by the editorial staff))

41 Revised: ((will be filled in by the editorial staff))

42 Published online: ((will be filled in by the editorial staff))  
43  
44  
45

### 46 **References**

- 47  
48 [1] K. Hu, B. R. Olsen, *J. Clin. Invest.* **2016**, *126*, 509.  
49  
50 [2] A. P. Kusumbe, S. K. Ramasamy, R. H. Adams, *Nature* **2014**, *507*, 323.  
51  
52 [3] S. Stegen, N. van Gestel, G. Carmeliet, *Bone* **2015**, *70*, 19.  
53  
54 [4] H. Mayer, H. Bertram, W. Lindenmaier, T. Korff, H. Weber, H. Weich, *J. Cell.*  
55  
56 *Biochem.* **2005**, *95*, 827.  
57  
58 [5] S. Javerzat, P. Auguste, A. Bikfalvi, *Trends Mol. Med.* **2002**, *8*, 483.  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [6] J.-M. Kim, H.-I. Shin, S.-S. Cha, C. S. Lee, B. S. Hong, S. Lim, H.-J. Jang, J. Kim, Y. R. Yang, Y.-H. Kim, S. Yun, G. Rijal, W. Lee-Kwon, J. K. Seo<sup>1</sup>, Y. S. Gho, S. H. Ryu, E.-M. Hur, P.-G. Suh, *Nat. Commun.* **2012**, *3*, 1296.
- [7] M. Raida, A. C. Heymann, C. Günther, D. Niederwieser, *Int. J. Mol. Med.* **2006**, *18*, 735.
- [8] D. M. Smadja, I. Bièche, J. S. Silvestre, S. Germain, A. Cornet, I. Laurendeau, J. P. Duong-Van-Huyen, J. Emmerich, M. Vidaud, M. Aiach, P. Gaussem, *Arterioscler. Thromb. Vasc. Biol.* **2008**, *28*, 2137.
- [9] L. A. Dyer, X. Pi, C. Patterson, *Trends Endocrinol. Metab.* **2014**, *25*, 472.
- [10] A. M. Parfitt, *Bone* **2000**, *26*, 319.
- [11] A. Barba, Y. Maazouz, A. Diez-Escudero, K. Rappe, M. Espanol, E. B. Montufar, C. Öhman-Mägi, C. Persson, P. Fontecha, M.-C. Manzanares, J. Franch, M.-P. Ginebra, *Acta Biomater.* **2018**, DOI: 10.1016/j.actbio.2018.09.003. [ahead of print]
- [12] A. Barba, A. Diez-Escudero, Y. Maazouz, K. Rappe, M. Espanol, E. B. Montufar, M. Bonany, J. M. Sadowska, J. Guillem-Marti, C. Öhman-Mägi, C. Persson, M.-C. Manzanares, J. Franch, M.-P. Ginebra, *ACS Appl. Mater. Interfaces* **2017**, *9*, 41722.
- [13] C. Danoux, D. Pereira, N. Döbelin, C. Stähli, J. Barralet, C. van Blitterswijk, P. Habibovic, *Adv. Healthc. Mater.* **2016**, *5*, 1775.
- [14] C. Danoux, L. Sun, G. Koçer, Z. T. Birgani, D. Barata, J. Barralet, C. Van Blitterswijk, R. Truckenmüller, P. Habibovic, *Adv. Mater.* **2016**, *28*, 1803.
- [15] X. Xiao, W. Wang, D. Liu, H. Zhang, P. Gao, L. Geng, Y. Yuan, J. Lu, Z. Wang, *Sci. Rep.* **2015**, *5*, 9409.
- [16] W. Chen, W. Thein-Han, M. D. Weir, Q. Chen, H. H. K. Xu, *Dent. Mater.* **2014**, *30*, 535.
- [17] Z. S. Patel, S. Young, Y. Tabata, J. A. Jansen, M. E. K. Wong, A. G. Mikos, *Bone* **2008**, *43*, 931.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [18] H. X. Zhang, X. P. Zhang, G. Y. Xiao, Y. Hou, L. Cheng, M. Si, S. S. Wang, Y. H. Li, L. Nie, *Mater. Sci. Eng. C* **2016**, *60*, 298.
- [19] J. Barralet, U. Gbureck, P. Habibovic, E. Vorndran, C. Gerard, C. J. Doillon, *Tissue Eng. Part A* **2009**, *15*, 1601.
- [20] S. Bose, G. Fielding, S. Tarafder, A. Bandyopadhyay, *Trends Biotechnol.* **2013**, *31*, 594.
- [21] W. Thein-Han, H. H. K. Xu, *Tissue Eng. Part A* **2013**, *19*, 1675.
- [22] M. M. L. Deckers, R. L. van Bezooijen, G. van der Horst, J. Hoogendam, C. van der Bent, S. E. Papapoulos, C. W. G. M. Löwik, *Endocrinology* **2002**, *143*, 1545.
- [23] H. von Schroeder, C. Veillette, J. Payandeh, A. Qureshi, J. N. Heersche, *Bone* **2003**, *33*, 673.
- [24] S. J. Bidarra, C. C. Barrias, M. A. Barbosa, R. Soares, J. Amédée, P. L. Granja, *Stem Cell Res.* **2011**, *7*, 186.
- [25] J. Ma, J. J. J. P. van den Beucken, F. Yang, S. K. Both, F.-Z. Cui, J. Pan, J. A. Jansen, *Tissue Eng. Part C. Methods* **2011**, *17*, 349.
- [26] Y. Kang, S. Kim, M. Fahrenholtz, A. Khademhosseini, Y. Yang, *Acta Biomater.* **2013**, *9*, 4906.
- [27] W. Sun, A. Motta, Y. Shi, A. Seekamp, H. Schmidt, S. N. Gorb, C. Migliaresi, S. Fuchs, *Biomed. Mater.* **2016**, *11*, 35009.
- [28] T. O. Pedersen, A. L. Blois, Y. Xue, Z. Xing, Y. Sun, A. Finne-Wistrand, J. B. Lorens, I. Fristad, K. N. Leknes, K. Mustafa, *Stem Cell Res. Ther.* **2014**, *5*, 23.
- [29] X. Liu, W. Chen, C. Zhang, W. Thein-Han, K. Hu, M. A. Reynolds, C. Bao, P. Wang, L. Zhao, H. H. K. Xu, *Tissue Eng. Part A* **2017**, *23*, 546.
- [30] A. Bouacida, P. Rosset, V. Trichet, F. Guilloton, N. Espagnolle, T. Cordonier, D. Heymann, P. Layrolle, L. Sensébé, F. Deschaseaux, *PLoS One* **2012**, *7*, e48648.
- [31] K. Janeczek Portalska, A. Leferink, N. Groen, H. Fernandes, L. Moroni, C. van

Blitterswijk, J. de Boer, *PLoS One* **2012**, 7, e46842.

- [32] J. König, B. Huppertz, G. Desoye, O. Parolini, J. D. Fröhlich, G. Weiss, G. Dohr, P. Sedlmayr, I. Lang, *Stem Cells Dev.* **2012**, 21, 1309.
- [33] C. Knabe, F. C. Driessens, J. a Planell, R. Gildenhaar, G. Berger, D. Reif, R. Fitzner, R. J. Radlanski, U. Gross, *J. Biomed. Mater. Res.* **2000**, 52, 498.
- [34] J. Gustavsson, M. P. P. Ginebra, E. Engel, J. Planell, *Acta Biomater.* **2011**, 7, 4242.
- [35] J. Gustavsson, M. P. Ginebra, J. Planell, E. Engel, *J. Mater. Sci. Mater. Med.* **2012**, 23, 2509.
- [36] J.-M. Sadowska, J. Guillem-Marti, E. B. Montufar, M. Espanol, M.-P. Ginebra, *Tissue Eng. Part A* **2017**, 23, 1297.
- [37] N. Vandecandelaere, C. Rey, C. Drouet, *J. Mater. Sci. Mater. Med.* **2012**, 23, 2593.
- [38] S. Cazalbou, D. Eichert, X. Ranz, C. Drouet, C. Combes, M. F. Harmand, C. Rey, *J. Mater. Sci. Mater. Med.* **2005**, 16, 405.
- [39] J. M. Sadowska, F. Wei, J. Guo, J. Guillem-Marti, M.-P. Ginebra, Y. Xiao, *Biomaterials* **2018**, 181, 318.
- [40] G. Ciapetti, G. Di Pompo, S. Avnet, D. Martini, A. Diez-Escudero, E. B. Montufar, M.-P. Ginebra, N. Baldini, *Acta Biomater.* **2017**, 50, 102.
- [41] J. M. Sadowska, J. Guillem-Marti, M. Espanol, C. Stähli, N. Döbelin, M.-P. Ginebra, *Acta Biomater.* **2018**, 76, 319.
- [42] A. Peng, T. Wu, C. Zeng, D. Rakheja, J. Zhu, T. Ye, J. Hutcheson, N.D. Vaziri, Z. Liu, C. Mohan, X.J. Zhou, *PLoS One.* **2011**, 6, e23268.
- [43] G. S. Di Marco, M. Hausberg, U. Hillebrand, P. Rustemeyer, W. Wittkowski, D. Lang, H. Pavenstädt, *Am. J. Physiol. Renal Physiol.* **2008**, 294, F1381.
- [44] C. Xu, F. Yang, S. Wang, S. Ramakrishna, *J. Biomed. Mater. Res. - Part A* **2004**, 71, 154.
- [45] J. A. Mmaier, D. Bernardini, Y. Rayssiguier, A. Mazur, *Biochimica et Biophysica Acta*

2004, 1689, 6.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [46] K. Sternberg, M. Gratz, K. Koeck, J. Mostertz, R. Begunk, M. Loebler, B. Semmling, A. Seidlitz, P. Hildebrandt, G. Homuth, N. Grabow, C. Tuemmler, W. Weitschies, K. P. Schmit, H. Kroemer, *J Biomed Mater Res Part B* **2012**, *100B*, 41.
- [47] E. Engel, S. Del Valle, C. Aparicio, G. Altankov, L. Asin, J. a Planell, M.-P. Ginebra, *Tissue Eng. Part A* **2008**, *14*, 1341.
- [48] Y. K. Y. K. Liu, Q. Z. Q. Z. Lu, R. Pei, H. J. H. J. Ji, G. S. G. S. Zhou, X. L. X. L. Zhao, R. K. R. K. Tang, M. Zhang, *Biomed. Mater.* **2009**, *4*, 025004.
- [49] S. Fuchs, X. Jiang, H. Schmidt, E. Dohle, S. Ghanaati, C. Orth, A. Hofmann, A. Motta, C. Migliaresi, C. J. Kirkpatrick, *Biomaterials* **2009**, *30*, 1329.
- [50] G. S. Di Marco, M. König, C. Stock, A. Wiesinger, U. Hillebrand, S. Reiermann, S. Reuter, S. Amler, G. Köhler, F. Buck, M. Fobker, P. Kumpers, H. Oberleithner, M. Hausberg, D. Lang, H. Pavenstädt, M. Brand, *Kidney Int.* **2013**, *83*, 213.
- [51] H. Peng, A. Usas, A. Olshanski, A. M. Ho, B. Gearhart, G. M. Cooper, J. Huard, *J. Bone Miner. Res.* **2005**, *20*, 2017.
- [52] N. Akeno, J. Robins, M. Zhang, M. F. Czyzyk-Krzeska, T. L. Clemens, *Endocrinology* **2002**, *143*, 420.
- [53] K. Eldesoqi, C. Seebach, C. Nguyen Ngoc, S. Meier, C. Nau, A. Schaible, I. Marzi, D. Henrich, *PLoS One* **2013**, *8*, e79058.
- [54] A. Aguirre, A. González, M. Navarro, Ó. Castaño, J. A. Planell, E. Engel, *Eur. Cells Mater.* **2012**, *24*, 90.
- [55] R. Olivares-Navarrete, S. L. Hyzy, R. A. Gittens, J. M. Schneider, D. A. Haithcock, P. F. Ullrich, P. J. Slosar, Z. Schwartz, B. D. Boyan, W. H. Coulter, *Spine J.* **2013**, *13*, 1563.
- [56] N. Ferrara, H.-P. Gerber, J. LeCouter, *Nat. Med.* **2003**, *9*, 669.
- [57] S. Koch, L. Claesson-Welsh, *Cold Spring Harb. Perspect. Med.* **2012**, *2*, 1.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [58] D. Salani, G. Taraboletti, L. Rosanò, V. Di Castro, P. Borsotti, R. Giavazzi, A. Bagnato, *Am. J. Pathol.* **2000**, *157*, 1703.
- [59] E. E. Golub, G. Harrison, a G. Taylor, S. Camper, I. M. Shapiro, *Bone Miner.* **1992**, *17*, 273.
- [60] H. I. Roach, *Cell Biol. Int.* **1994**, *18*, 617.
- [61] S. Vasseur, S. Afzal, J. Tardivel-Lacombe, D. S. Park, J. L. Iovanna, T. W. Mak, *Proc. Natl. Acad. Sci.* **2009**, *106*, 1111.
- [62] J. Hoogendam, C. V. a N. D. E. R. Bent, S. E. Papapoulos, C. W. G. M. Lo, *Endocrinology* **2014**, *143*, 1545.
- [63] U. Bulnheim, P. Müller, H. Neumann, K. Peters, R. E. Unger, C. J. Kirkpatrick, J. Rychly, *J. Tissue Eng. Regen. Med.* **2014**, *8*, 831.
- [64] R. McBeath, D. M. Pirone, C. M. Nelson, K. Bhadriraju, C. S. Chen, *Dev. Cell* **2004**, *6*, 483.
- [65] K. A. Kilian, B. Bugarija, B. T. Lahn, M. Mrksich, *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 4872.
- [66] F. Villars, B. Guillotin, T. Amédée, S. Dutoya, L. Bordenave, R. Bareille, J. Amédée, *Am. J. Physiol. Cell Physiol.* **2002**, *282*, C775.
- [67] D. Kaigler, P. H. Krebsbach, E. R. West, K. Horger, Y.-C. Huang, D. J. Mooney, *FASEB J.* **2005**, *19*, 665.
- [68] M. P. Ginebra, E. Fernandez, E. a. P. A. De Maeyer, R. M. H. M. Verbeeck, M. G. G. Boltong, J. Ginebra, F. C. Driessens, J. A. A. Planell, *J. Dent. Res.* **1997**, *76*, 905.
- [69] M. Espanol, R. A. Perez, E. B. Montufar, C. Marichal, A. Sacco, M. P. Ginebra, *Acta Biomater.* **2009**, *5*, 2752.
- [70] F. H. Chung, *J. Appl. Crystallogr.* **1974**, *7*, 519.
- [71] A. Diez-Escudero, M. Espanol, S. Beats, M.-P. Ginebra, *Acta Biomater.* **2017**, *60*, 81.
- [72] A. Aguirre, A. González, J. A. Planell, E. Engel, *Biochem. Biophys. Res. Commun.*


2010, 393, 156.

[73] A. Aguirre, J. A. Planell, E. Engel, *Biochem. Biophys. Res. Commun.* **2010**, 400, 284.


[74] J. Stern, W. H. P. Lewis, *Clin. Chim. Acta* **1957**, 2, 576.

[75] J. Gitelman, *Anal. Biochem.* **1967**, 18, 521.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



**Figure 1.** Physicochemical characterization of CaPs A) SEM micrographs of surface morphology. Scale bare denotes 2  $\mu\text{m}$ . B) Optical interferometry images of C-CDHA, F-CDHA and  $\beta$ -TCP. C) XRD patterns of the different calcium phosphate substrates. The vertical lines represent the patterns of HA (JCPDS 82-1943),  $\alpha$ -TCP (JCPDS 09-0348) and  $\beta$ -TCP (JCPDS 70-2065) from the Joint Committee on powder Diffraction Standards. D) Values of roughness, specific surface area (SSA) and total porosity.<sup>[71]</sup>




**Figure 2.** A) Proliferation of monocultured rEPCs, monocultured rMSCs and cocultured cells with ratio 1:2 of rEPCs and rMSCs on various CaPs. Cell numbers were quantified at 6 hours, 3 days, 7 days, 14 days and 21 days (n=6). The values were expressed as relative fold change compared to cell number obtained on corresponding TCPS at 6 hours. In all graphs, the same letter (a, b or c) indicate groups with no statistically significant differences ( $p > 0.05$ ) at specific time point. B) Calcium concentration in EGM-2 MV medium in presence of cells (n=6). C) Phosphate concentration in EGM-2 MV medium in presence of cells (n=6).




**Figure 3.** Merged fluorescence images of monocultured rEPCs, monocultured rMSCs and cocultured cells with ratio 1:2 of rEPCs and rMSCs on various CaPs. Cells were stained for F-actin (red) and nuclei (blue). The images were acquired at 14 days and 21 days of cell culture. The cells seeded on glass coverslip were used as a control. Scale bar denotes 50  $\mu\text{m}$ .






**Figure 4.** Merged fluorescence images of monocultured rEPCs, monocultured rMSCs and cocultured cells with ratio 1:2 of rEPCs and rMSCs on C-CDHA, F-CDHA and  $\beta$ -TCP at 14 and 21 days of cell culture. Cells were stained for Connexin43 (green), F-actin (red) and nuclei (blue). Scale bars denote 50  $\mu$ m in the main images and 10  $\mu$ m in the insets.




**Figure 5.** A) Merged fluorescence images of monocultured rEPCs and cocultured cells at ratio 1:2 of rEPCs and rMSCs on C-CDHA, F-CDHA and  $\beta$ -TCP at 14 and 21 days of cell culture. Cells were stained for PECAM-1 (green) and nuclei (blue). For coculture images, cells stained with both PECAM-1 and nuclei correspond to rEPCs whilst cells without PECAM-1 staining represent rMSCs. Scale bar denotes 200  $\mu$ m for the main images and 50  $\mu$ m for magnified images. B) Semiquantitative evaluation of area of PECAM-1 staining in monocultured rEPCs on CaPs at 14 and 21 days (n=10). C) Semiquantitative evaluation of the area of PECAM-1 staining in cocultured 1:2 rEPCs and rMSCs on CaPs at 14 and 21 days (n=10). In graphs B and C, the same letter indicates groups with no statistically significant differences ( $p > 0.05$ ) at specific time point.

▨ rEPCs monoculture    ■ rMSCs monoculture    ▩ 1:2 rEPCs: rMSCs coculture




**Figure 6.** Gene expression of osteogenic markers in monocultured rEPCs, monocultured rMSCs and coculture on three calcium phosphate substrates (n=6). Expressions levels were determined by quantitative real time RT-PCR, normalised versus monocultured rMSCs on TCPS at 1 day and displayed relative to their housekeeping gene. In all graphs, the same letter (a, b, c or d) indicates no statistically significant differences ( $p > 0.05$ ) between substrates for each specific cell culture condition (rEPCs monoculture, rMSCs monoculture, rEPCs: rMSCs

coculture). The same number (1, 2 or 3) indicates no statistically significant differences ( $p > 0.05$ ) between cell culture conditions for each substrate (C-CDHA, F-CDHA,  $\beta$ -TCP, TCPS).



**Figure 7.** Gene expression of angiogenic markers in monocultured rEPCs, monocultured rMSCs and coculture on three calcium phosphate substrates (n=6). Expressions levels were determined by quantitative real time RT-PCR, normalised versus monocultured rEPCs on TCPS at 1 day. and displayed relative to their housekeeping gene. In all graphs, the same letter (a, b, c or d) indicates no statistically significant differences ( $p > 0.05$ ) between substrates for each specific cell culture condition (rEPCs monoculture, rMSCs monoculture, rEPCs: rMSCs coculture). The same number (1, 2 or 3) indicates no statistically significant differences ( $p > 0.05$ ) between cell culture conditions for each substrate (C-CDHA, F-CDHA,  $\beta$ -TCP, TCPS).





**Figure 8.** A) Effect of culturing both rEPCs and rMSCs on the gene expression of osteogenesis and angiogenesis related genes compared to monocultured cells (n=6). In order to see either specific gene is upregulated in coculture system the gene expression was normalised versus gene expression in monocultured rMSCs or monocultured rEPCs for osteogenic (ALP, BMP-2, OC, DJ 1) or angiogenic (VEGF A, VEGF R2, EDH 1) genes, respectively. For samples where gene expression in monoculture was not detected the mean value obtained in coculture was plotted (\*). In all graphs, the same letter (a, b, c or d) indicates no statistically significant differences ( $p > 0.05$ ) between substrates for each specific time point. B) Heat map of gene upregulation in coculture system.



Click here to access/download

**Supporting Information**

Sadowska AHM Supporting information.docx





[Click here to access/download](#)

**Production Data**

Sadowska AHM fv manuscript-production data.doc





[Click here to access/download](#)

**Production Data**

**Sadowska AHM summary and ToC.docx**








[Click here to access/download](#)

**Production Data**

**Sadowska AHM Table of contents.tif**





Click here to access/download

**Production Data**

Sadowska AHM Supporting information-production  
data.docx



















Click here to access/download  
**Production Data**  
**FIGURE 8.tif**